Comparison
DSIP vs. Leuprorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
62568-57-4
53714-56-0
Molecular weight
848.81 g/mol
1209.4 g/mol
Half-life
0.1 h
3 h
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluPyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEtMechanism of action
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Leuprorelin
Leuprorelin is a GnRH-receptor agonist. After binding to pituitary GnRH receptors, it first causes a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release — the so-called flare. With continuous, non-pulsatile exposure the receptors are downregulated and desensitized, suppressing gonadotropin secretion and consequently lowering sex steroids (testosterone or estradiol) to low levels. This mechanism underlies the literature-described use in hormone-dependent conditions.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
4
of which in humans
1
4
Effects recorded
3
4
Open conflicts
1
1
Documented adverse events
1
3
Legal status
Full entries
Frequently asked questions
- What is the difference between DSIP and Leuprorelin?
- DSIP is classified as "Research other", while Leuprorelin is classified as "Research other". DSIP: Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations. Leuprorelin: Leuprorelin (also leuprolide) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH). It is an approved prescription medicine in several jurisdictions, including for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, DSIP or Leuprorelin?
- The highest available evidence level is "Human trial" for DSIP and "Human RCT" for Leuprorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of DSIP and Leuprorelin in Germany and the United States?
- Germany: DSIP — Unapproved, Leuprorelin — Prescription. United States: DSIP — Unapproved, Leuprorelin — Prescription. These are factual summaries with source and review date on the individual pages.